Skip to main content
. 2020 Sep 15;12(9):5940–5954.

Figure 2.

Figure 2

The value of lnc-MALAT1, miR-125b, FOXQ1, PTGS2 and CDK5 for distinguishing AD patients from Ctrls and PD patients. The performance of CSF lnc-MALAT1, miR-125b, FOXQ1, PTGS2 and CDK5 in differentiating AD patients from Ctrls (A) and PD patients (B). The performance of plasma lnc-MALAT1, miR-125b, FOXQ1, PTGS2 and CDK5 in discriminating AD patients from Ctrls (C) and PD patients (D). The abilities of lnc-MALAT1, miR-125b, FOXQ1, PTGS2 and CDK5 in distinguishing AD patients from Ctrls or in distinguishing AD patients from PD patients were illuminated by ROC curve and AUC with 95% CI. Lnc-MALAT1, long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1; miR-125b, microRNA 125b; FOXQ1, forkhead box Q1; PTGS2, prostaglandin-endoperoxide synthase 2; CDK5, cyclin dependent kinase 5; AD, Alzheimer’s disease; Ctrls, controls; PD, Parkinson’s disease; CSF, cerebrospinal fluid; ROC, Receiver operating characteristic; AUC, area under the curve; CI, confidence interval.